Zhu Chen honored by American Association for Cancer Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ZHU CHEN was honored by the American Association for Cancer Research with its Award for Distinguished Public Service and Global Impact in Cancer Research in Biomedical Science.

Chen, a fellow of the AACR Academy, is the vice chairman of the 12th Standing Committee of the National People’s Congress. From 2007 to 2013, he served as China’s minister of health. He received the award Oct. 9, where he delivered the opening plenary lecture at the AACR’s inaugural meeting in China.

Chen helped pioneer the concept of combination targeted therapies for cancer and, by combining traditional Chinese medicine with Western medicine, he provided the first successful model in the treatment of acute promyeloctyic leukemia with all-trans retinoic acid and arsenic trioxide.

Under Chen’s leadership, the Chinese National Human Genome Center has contributed to human genome sequencing and SNP HaploMap projects. They recently completed genome sequencing of Schistosoma japonicum, which revealed features of a host-parasite interplay that lead to better control and prevention of infection, a disease that remains a significant health problem in China.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login